Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group
This analysis compares 1689 multiple myeloma patients under the age of 50 with 8860 patients at least 50 years old or older. Distinguishing factors from the younger group were that myeloma was more common among men, had a low International Staging System (ISS) stage, had a low Durie-Salmon stage, and less prognostic factors. Younger patients also had longer survival rates, with up to 10 years for 19% after conventional therapy and 43% after high-dose therapy. In the older group, their 10-year survival rate was 8% after conventional therapy and 29% after high- dose therapy. “In conclusion, patients with myeloma younger than 50 years of age had significantly longer age-adjusted survival both after conventional and high-dose therapy (5.4 and 7.5 years, respectively) in relation to older patients (3.7 and 5.7 years, respectively).” This study demonstrates that younger patients experience better outcomes because they often present “with a lower ISS stage at diagnosis and other more favorable prognostic features.”
Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J.
Learn more at: